Loading…
Hosted by ReachMD · 🇺🇸 US · EN · 181 episodes
Established thought leaders with verified media credentials.
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
ReachMD hosts Project Oncology®, a science show with 181 episodes published.
Host: Steve Jackson, PharmD Guest: Jahan Aghalar, MD Guest: Ulka Vaishampayan, MD With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyda
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bilal Siddiqui, MD Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consi
Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatme
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA -mutated disease who progress after a CDK4/6 i
Host: Steve Jackson, PharmD Guest: Matthew J. Matasar, MD Guest: Tycel Phillips, MD This is a non-certified educational series produced and controlled by ReachMD. Timely referral for CAR T-cell therapy remains a critical
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speak
Host: John Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat
Host: Matt Birnholz, MD Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide. Host
Host: Jacob Sands, MD Guest: Edith Mitchell, MD, MACP, FCPP, FRCP Widespread health disparities have led to challenges in colorectal cancer screening. What's causing these disparities—and what are some ways we can overco
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Guru P. Sonpavde, MD What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pooja Ghatalia, MD Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel ap
Host: Brian P. McDonough, MD, FAAFP Guest: Tara Graff, DO, MS Guest: Surbhi Sidana, MD This is a non-certified educational series produced and controlled by ReachMD. While BCMA-directed CAR T-cell therapy has changed the
Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented
Host: Jennifer Caudle, DO, FACOFP Guest: Mansi R. Shah, MD This is a non-certified educational series produced and controlled by ReachMD. The latest International Myeloma Working Group (IMWG) guidelines emphasize immune
Presenter: Ryan Quigley Not all metastatic breast cancer is created equal. This AudioAbstract spotlights new data from a multicenter study in Japan that highlights how the first site of distant recurrence can significant
Guest: John H. Strickler, MD The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. Jo
Guest: William Hall, MD From tumor detection to biomarker development, artificial intelligence (AI) is rapidly reshaping the landscape of gastrointestinal oncology. In this expert-led program, Dr. William Hall explains h
Guest: Daniela Molena, MD For patients with locally advanced gastroesophageal cancer, surgery remains a critical component of curative treatment—even in the era of chemoradiation and advanced imaging. Dr. Daniela Molena
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients wi
Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast can
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Project Oncology® has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Project Oncology® is hosted by ReachMD. The show is categorised under science (medicine) and has published 181 episodes.
Project Oncology® has published 181 episodes.
Project Oncology® regularly covers science, medicine, health. It sits in the science category, with a medicine focus.
Project Oncology® is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Project Oncology® hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Project Oncology® average 11 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Project Oncology®'s guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched today.